Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung Cancer An One-arm, Phase Ⅱ, Multi-center Clinical Study (SALTER TRIAL)

Trial Profile

S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung Cancer An One-arm, Phase Ⅱ, Multi-center Clinical Study (SALTER TRIAL)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 27 Sep 2024 Results (n=71) assessing the efficacy and safety of anlotinib combination with oral fluoropyrimidine S1 in patients with Refractory or Relapsed SCLC published in the BMC Cancer.
  • 22 Feb 2023 Status changed from recruiting to completed.
  • 21 Sep 2021 Results (n=71; Between March 2019 to June 2020) assessing the efficacy and safety of anlotinib combination with oral fluoropyrimidine S1 in patients with Refractory or Relapsed small cell lung cancer, presented at the 46th European Society for Medical Oncology Congress.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top